AUC in Sprague-Dawley rat at 10 mg/kg, po dosed as aqueous suspension of 1% polysorbate 80 in 0.5% methylcellulose after 0.25 to 24 hrs by LC/MS/MS analysis
Cmax in Sprague-Dawley rat at 10 mg/kg, po dosed as aqueous suspension of 1% polysorbate 80 in 0.5% methylcellulose after 2 to 4 hrs by LC/MS/MS analysis
Oral bioavailability in Sprague-Dawley rat at 10 mg/kg dosed as aqueous suspension of 1% polysorbate 80 in 0.5% methylcellulose after 0.25 to 24 hrs by LC/MS/MS analysis
AUC in Sprague-Dawley rat at 10 mg/kg, po dosed as aqueous suspension of Labrafil M 1944CS/DMAC/polysorbate 80, 85:10:5 (v/v) after 0.25 to 24 hrs by LC/MS/MS analysis
Cmax in Sprague-Dawley rat at 10 mg/kg, po dosed as aqueous suspension of Labrafil M 1944CS/DMAC/polysorbate 80, 85:10:5 (v/v) after 2 to 4 hrs by LC/MS/MS analysis
Oral bioavailability in Sprague-Dawley rat at 10 mg/kg dosed as aqueous suspension of Labrafil M 1944CS/DMAC/polysorbate 80, 85:10:5 (v/v) after 0.25 to 24 hrs by LC/MS/MS analysis
Metabolic stability in NADPH-fortified human liver microsomes assessed as pyrazinone oxidation metabolite formation at 10 uM after 30 mins by HPLC/UV/MS analysis
Metabolic stability in NADPH-fortified rat liver microsomes assessed as pyrazinone oxidation metabolite formation at 10 uM after 30 mins by HPLC/UV/MS analysis